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Amyloid formationLipopolysaccharide (LPS), the important component of the outer membrane of Gram-negative bacteria, contrib-
utes to the integrity of the outermembrane and protects the cell against bactericidal agents, including antimicro-
bial peptides. However, the mechanisms of interaction between antimicrobial peptides and LPS are not clearly
understood. Halictines-2 (HAL-2), one of the novel antimicrobial peptides, was isolated from the venom of the
eusocial bee Halictus sexcinctus. HAL-2 has exhibited potent antimicrobial activity against Gram-positive and
Gram-negative bacteria and even against cancer cells. Here, we studied the interactions between HAL-2 and
LPS to elucidate the antibacterial mechanism of HAL-2 in vitro. Our results show that HAL-2 adopts a signiﬁcant
degree of β-strand structure in the presence of LPS. LPS is capable of inducing HAL-2 amyloid formation, which
may play a vital role in its antimicrobial activity.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Antibiotics have revolutionised the treatment of common bacterial
infections. However, the widespread and frequent intake of antibiotics
in small doses constitutes a constant selective pressure on pathogens
and results in antibiotic-resistant strains [1]. Antibiotic resistance is
the ability of a microorganism to withstand the effects of an antimicro-
bial agent as a result of chromosomal changes or the exchange of genet-
ic material via plasmids and transposons [2]. This genetic variability of
pathogens is a serious threat to public health, thereby creating a contin-
uous need to develop new antibiotics.
Antimicrobial peptides (AMPs) are evolved host defence effector
molecules that are produced by a wide variety of organisms, ranging
from prokaryotes to humans [3–5]. AMPs possess an unusually broad
spectrum of activity and are promising candidates for the development
of therapeutic drugs in the ﬁght against resistant pathogens [6–9]. The
antibiotic action of most of AMPs stems from their ability to make the
membrane permeable, though thatmay not be their solemode of action
[8,10,11]. Despite their diverse origins, AMPs share a common charac-
teristic of harbouring small, positively charged, amphipathic struc-
tures [12,13]. The net cationicity and amphipathicity of AMPs
mediates the interaction between AMPs and the highly anionic lipo-
polysaccharide (LPS) of Gram-negative bacteria, which constitutes the
lipid portion of the outer membrane; this interaction causes the leakage
of essential cell contents by forming pores or disturbing the lipid6 551 65595669.
@hmﬂ.ac.cn (J. Wang).organisation [14–16]. It has been reported that many AMPs are able to
neutralise the endotoxic effect of LPS on immune cells [17–20]. There-
fore, studies on the structure of AMPs and their interactions with LPS
are vital to improve our understanding of the antibacterial mechanisms
of AMPs and to help design new antimicrobial peptides for therapeutic
purposes.
A large number of AMPs have been derived from toxin-related poly-
peptides, such as the animal venoms from scorpions [21], spiders [22],
bees [23], and snakes [24]. Due to their different mechanisms of action
and incredible versatility, they have demonstrated an interesting alter-
native for controllingmicroorganisms that are resistant to conventional
antibiotics. Halictines-2 (HAL-2, Gly-Lys-Trp-Met-Ser-Leu-Leu-Lys-His-
Ile-Leu-Lys-NH2) is one of the shortest cationic AMPs isolated from the
venom of the wild eusocial bee Halictus sexcinctus [25]. It has been re-
ported that HAL-2 is active against Gram-positive and Gram-negative
bacteria, the yeast pathogen Candida albicans, and has sufﬁcient potency
to kill several types of cancer cells.
The aim of this workwas to study themolecularmechanism of HAL-
2 antimicrobial activity. We focused on the interactions between HAL-2
and LPS, the Gram-negative bacterial cell wall barrier that broad-
spectrum AMPs are able to break. The interaction of HAL-2 with LPS
was investigated using various physicochemical methods, including cir-
cular dichroism (CD), nuclear magnetic resonance (NMR), surface plas-
mon resonance (SPR) and Thioﬂavin T (ThT) ﬂuorescence. Our results
show that HAL-2 interacts with LPS lipid and adopts a signiﬁcant degree
of β-strand structure to form amyloid aggregates. In comparison to
HAL-2, three analogues that form less amyloid lost most of their antimi-
crobial activity. These results strongly suggest that the HAL-2 amyloid
aggregates induced by LPS contribute to its antimicrobial activity.
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2.1. Peptide preparation
Synthetic antimicrobial peptideHAL-2 (GKWMSLLKHILK) and its ana-
logues HAL-2L6(D) (GKWMSL(D)LKHILK), HAL-2K8P (GKWMSLLPHILK)
and HAL-2H9P (GKWMSLLKPILK) were commercially provided by GL
Biochem Ltd (Shanghai, China). The purity of the synthetic peptide used
to evaluate biological activity was higher than 95%. Based on the amino
acid sequence of HAL-2, the gene sequence encoding HAL-2 was synthe-
sised by Genscript (Nanjing, China). Then, the HAL-2 gene was cloned
into a modiﬁed vector pET22b to produce sumo fusion protein, and the
cloningwas veriﬁed by DNA sequencing. The peptide used for NMR stud-
ies was expressed in Escherichia coli BL21(DE3)/pLysS cells grown on
minimal M9 medium supplemented with [15N]ammonium chloride
(Cambridge Isotope Laboratories). The fusion protein containing the pep-
tide was afﬁnity puriﬁed from the clariﬁed supernatant with Ni2+-NTA
agarose resin (GE healthcare), and it was puriﬁed to homogeneity by
fast protein liquid chromatography (GE healthcare). After cleavage by
sumo-enzyme, the peptide was puriﬁed by reverse-phase HPLC (Bio-
Rad, America) using a C18 semi-preparative column (Waters), and it
was then lyophilised and analysed by ESI-MS.
2.2. Assessment of cell viability
In vitro time viability loss curves for HAL-2 were determined. Expo-
nentially growing E. coli ATCC 25922 cells were resuspended in buffer at
pH 7.4 (20mMTris, 100mMNaCl) to obtain a density of 2 × 108 cfu/mL.
The bacterial suspensions were incubated at 37 °C for increasing time
intervals (from 20 to 180 min) with HAL-2 at concentrations of 20, 40,
and 60 μM. After incubation, samples (10 μL) were removed from each
well and diluted appropriately in buffer. Colony-forming units (CFUs)
were determined by spotting 20 μL of serial dilution samples onto
Mueller-Hinton agar plates, with an 18-hour incubation at 37 °C. For
HAL-2 analogues, the bacterial suspensions were incubated at 37 °C
for 180 min with peptides at concentrations of 60 μM.
2.3. Flow cytometry analysis
The effects of HAL-2 on bacterial membrane integrity were
determined. In brief, E. coli ATCC 25922 cultures were resuspended at
2 × 108 cfu/mL in 1 mL buffer at pH 7.4 (20 mM Tris, 100 mM NaCl).
The HAL-2 was added at concentrations of 20, 40, and 60 μM, and the
samples were incubated at 37 °C for 180 min. The bacterial cells were
harvested by centrifugation, resuspended in 1 mL buffer and incubated
for 30 min in the dark at room temperature with PI (5 μg/mL ﬁnal con-
centration, Sigma, USA). Flow cytometry (Becton–Dickinson) measure-
ments were performed immediately thereafter.
2.4. Scanning electron microscopy (SEM)
The morphology changes induced by peptide HAL-2 on E. coli ATCC
25922 were studied using scanning electron microscopy, according to
amodiﬁed procedure adapted fromWei et al. [26]. Accordingly, bacteria
were resuspended at 2 × 108 cfu/mL in buffer at pH 7.4 (20 mM Tris,
100mMNaCl) and incubated at 37 °C for 180 min with HAL-2 at differ-
ent concentrations (20, 40, 60 μM). Then, an aliquot (10 μL) of each sam-
ple was serially diluted and plated onto Mueller-Hinton agar for a CFU
count. The remaining bacterial cells were centrifuged at 8000 rpm for
5 min, and the pellet was ﬁxed with 2.5% glutaraldehyde in PBS
(pH 7.4) for 2 h at room temperature. After twowashes with phosphate
buffer saline (PBS), the cellswere postﬁxedwith 2% (w/v) AuCl3·HCl for
2 h, dehydrated in a graded series of ethanol, exchanged ethanol with
tert-butyl alcohol; this mixture was then deposited on silicon wafers,
frozen in liquid nitrogen, and then vacuum-dried overnight. After
gold-plating and mounting onto aluminium stubs, the samples wereanalysedwith Helios NanoLab™ 600i SEM following themanufacturer's
instruction.
2.5. Circular dichroism (CD) spectroscopy
Circular dichroism (CD) experiments were carried out on a Jasco J-
810 spectropolarimeter (Tokyo, Japan). The CD spectra of the HAL-2
and its analogues were recorded at room temperature from 190 to
240 nm. CD spectroscopy was used to investigate the secondary struc-
ture adopted by HAL-2 and its analogues in the absence and presence
of LPS (2 mg/mL) from E. coli 055:B5 (Sigma). Peptides were dissolved
at 0.2 mg/mL in buffer at pH 7.4 (20 mM Tris) for all CD experiments.
The spectra were collected as averages over three scans using a 1-mm
path length cell. A 1 nm data pitch, 100 nm/min scanning speed, 1 s re-
sponse time and 1 nm bandwidth were generally used.
2.6. Nuclear magnetic resonance (NMR) spectroscopy
NMR experiments were recorded at 298 K on a 500 MHz Bruker
spectrometer (Germany) equipped with a cryo-probe and pulse ﬁeld
gradients. 2D 1H/15N HSQC spectra were acquired on samples of uni-
formly 1 mM 15N-labelled HAL-2 in the absence or presence of 0.05,
0.5, 1 mg/mL LPS. The experiments were performed in 20 mM Tris
(pH 7.4), 100 mM NaCl. All spectra were processed and analysed by
using the spectral processing and analysis systems NMRPipe and
Sparky.
Interactions of HAL-2 with LPS were also examined by recording a
series of one-dimensional 31P NMR spectra of LPS at 298 K, whereby
4 mg/mL LPS in 20 mM Tris (pH 7.4), 100 mM NaCl was titrated with
various concentrations (0.1, 0.2, 0.4, 0.8 and 1.0 mM) of peptide from
a stock solution thatwas prepared in buffer at pH7.4. The 31PNMRspec-
trawere recorded on a Bruker 850MHz spectrometer equippedwith 31P
direct-detection channel.
2.7. Surface plasmon resonance (SPR) experiments
The real-time binding interaction between HAL-2 and LPS wasmea-
sured by SPR using a Biacore 3000 instrument (GE Healthcare) at 25 °C.
The peptidewas covalently immobilised on the certiﬁed gradeCM5 sen-
sor chips at concentrations of 0.2 mM in 10 mM sodium acetate buffer,
pH 4.5, using the amine coupling kit according to themanufacturer's in-
structions. Brieﬂy, nearly 900 resonance units (RUs) of the peptidewere
immobilised under these conditions. The unreactedmoieties on the sur-
face were blocked with ethanolamine. All measurements were carried
out in 20 mM Tris (pH 7.4), 100 mM NaCl. LPS in running buffer (20 mM
Tris, 100 mMNaCl, pH 7.4) ﬂowed over the surface at concentrations of 1,
2, 4, 8, and 16 μg/mL at 25 °C and a ﬂow rate of 10 μL/min. After each
injection, the surface was regenerated with 140 μMHAL-2, 50 mM NaOH
and 50 mM NaOH containing 0.05% (w/v) SDS. The value of the binding
afﬁnity of LPS for HAL-2 was determined using the BIAevaluation 4.1 soft-
ware (Biacore), selecting the 1:1 Langmuir binding model for the kinetic
calculation.
2.8. Thioﬂavin T ﬂuorescence
Thioﬂavin T (ThT) has beenwidely used for the detection of amyloid
ﬁbrils because there is a large enhancement of its ﬂuorescence emission
when it binds to the cross-β architecture of amyloid. ThT displays exci-
tation maximums (ex) and emission maximums (em) that shift from
~385/445 nm for the free form to ~450/482 nm for the bound form
[27]. A stock solution of 10 mM ThT was prepared in Milli-Q water
and stored at 4 °C, protected from light to prevent quenching. For ThT
ﬂuorescence assays, 150 μL solutions, at pH 7.4 (20 mM Tris, 100 mM
NaCl), containing 1 mg/mL LPS and 40–140 μM HAL-2 or its analogues
with 47 μM ThT, were incubated in 96-microwell plates (while kept in
the dark). A SpectraMax M5 multidetection reader (Molecular Devices
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emission at 484 nm. Three replicates corresponding to three wells were
measured for each sample to allow for well-to-well variation. All mea-
surements were taken at 20 °C.
The samples for assessment of HAL-2 aggregation induced by E. coli
were prepared in the sameway as for ThT assays, except LPS (1mg/mL)
was replaced with E. coli (4 × 108 cfu/mL).3. Results
3.1. Expression and puriﬁcation of recombinant 15N-labelled HAL-2
A sequence encoding theHAL-2 peptidewas directly introduced into
a modiﬁed vector pET22b to produce sumo fusion protein (Fig. 1A). For
15N-labelled HAL-2, the recombinant plasmid was overexpressed in
E. coli BL21(DE3)/pLysS cells grown on minimal M9 medium supple-
mented with [15N]ammonium chloride. Recombinant HAL-2 was ﬁrst
puriﬁed with Ni2+-NTA afﬁnity chromatography, then cleaved with
sumo-enzyme, and ﬁnally eluted through a C18 semi-preparative col-
umn with approximately 40% acetonitrile that contained 0.1%Fig. 1. Cloning, expression and puriﬁcation of 15N-labelled HAL-2. (A) Schematic diagram of th
(C) ESI-MS analysis of puriﬁed HAL-2 products.triﬂuoroacetic acid. The puriﬁedHAL-2was visible as a peptide band ap-
proximately 1.4 kDa with slight sumo contaminants, as shown in
Tricine-SDS-PAGE (Fig. 1B). This gel fraction was further subjected to
molecular weight identiﬁcation by ESI-MS. The ESI-MS charged ion
mass values of (m + 3H)+/3 (1470.78 Da) and (m + 2H)+/2
(1470.56 Da) (Fig. 1C) matched perfectly with the calculated value of
1453.8 Da, combined with the MW increase from the 18 15N nitrogen
isotopes (http://cn.expasy.org/cgi-bin/pi_tool).3.2. Antimicrobial effects of HAL-2 on E. coli ATCC 25922
HAL-2 has been reported to possess high antimicrobial potency
against the two Gram-positive and two Gram-negative bacteria. In the
present study, E. coliATCC 25922was used to study the antimicrobial ef-
fects of HAL-2. Three HAL-2 concentrations (20, 40 and 60 μM) were
tested for bactericidal activity after incubation at pH 7.4 for 180 min.
The kinetics of growth of a culture treated with HAL-2 antibiotic was
monitored by the traditional viability counting on agar. As shown in
Fig. 2A, the HAL-2 exhibited an obvious dose-dependent antibacterial
activity within 180 min. In the ﬁrst 20 min, the viability of E. colie pET22b expression plasmid; (B) Tricine-SDS-PAGE analysis of HAL-2 after puriﬁcation;
Fig. 2. Bacterial viability of E. coli ATCC 25922 after treatment with HAL-2 at pH 7.4. (A) Loss of viability of E. coli after incubation with HAL-2. Bacteria were incubated for different incu-
bation timeswith 20, 40, or 60 μMofHAL-2. Data are themeans± standard deviation of three independent experiments. (B) CFU counts of E. coli incubatedwith 20, 40, or 60 μMofHAL-2
at pH 7.4 for 180 min. (C) Flow cytometry analysis of internalisation of PI by HAL-2 treated E. coli. Exponential phase bacterial cells were treated with HAL-2 at pH 7.4, and cellular ﬂuo-
rescence was analysed by ﬂow cytometry. CTRL, without peptide, negative control; HAL-2 was used at concentrations of 20, 40, 60 μM; percentages of PI positive cells are indicated.
(D) SEMofHAL-2 treated E. coli at pH7.4. CTRL, control bacteria incubatedwithout peptide; bacteria treatedwithHAL-2 at concentrations of 20, 40, and 60 μMfor up to 180min are shown.
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Then, the number of colony-forming units (CFUs) recovered for the
E. coli incubated with 20 and 40 μM HAL-2. The incubation of E. coli
with 60 μM of peptide showed a greater antimicrobial activity.
Cell membrane integrity was monitored by assessing the inter-
nalisation of a membrane impermeable ﬂuorescent dye, propidium
iodide (PI), using ﬂow cytometry. Damage to a cell membrane allows
PI, a small cationic molecule, to enter the cell and bind to nucleic acid,
thereby providing a rapid detection of antibiotic susceptibility [28].
E. coli ATCC 25922 bacterial cells were treated with different concentra-
tions of HAL-2 at pH 7.4 and incubated with PI (5 μg/mL) for 30 min;
they were then subjected to ﬂow cytometric analysis. Bacterial cells
suspended in buffer and exposed only to PI were used as negative con-
trols. As demonstrated in Fig. 2C, PI positive E. coli cellswere observed in
a signiﬁcant dose-dependent manner for HAL-2 concentrations of
20 μM (45.3%), 40 μM (62.2%) and 60 μM (83.3%), which agreed with
the CFU count results (Fig. 2A and B).
The cell morphology changes by HAL-2were further characterised by
SEM. The images of untreated bacterial cells displayed a smooth bright
surface with no apparent cellular debris. In contrast, peptide-exposed
cells exhibited a wide range of pronounced morphological change
(Fig. 2D). This mainly included deep roughening of the cell surface, the
collapse of the cell structure and the loss of bacterial integrity on account
of breakage. These phenomena differ from most antimicrobial peptides,which cause blebs on the microbial surface or partial loss of cell content
[26,29,30].
3.3. Interactions between HAL-2 and LPS
The secondary structure change of HAL-2 was analysed by CD spec-
troscopy. In aqueous buffer, the far-UV CD spectrum of HAL-2 showed a
strong negative band at 200 nm (Fig. 3A), an indication of a random-
coil-like conformation. This is consistent with a previous report that
the HAL-2 is unstructured in water [25]. In the presence of LPS, a mem-
brane mimetic environment, HAL-2 disclosed a strong positive band
near 195 nm and a negative maximum near 210 nm, suggesting that it
can adopt a signiﬁcant degree of secondary structure (Fig. 3A). More
β-sheet (53.3%), rather than the α-helical conformation of native HAL-
2, was induced by LPS. This change from a random-coil-like conforma-
tion to a folded conformation for HAL-2 is most likely caused by the
electrostatic interaction between the positively charged residues in
HAL-2 and the negatively charged LPS head group.
To further characterise the HAL-2 and LPS interaction, we utilised
the high-resolution 31P NMR technique to study the interaction from
the LPS perspective. Because the interaction between the phosphate
head groups of LPS and the active peptide HAL-2 causes local chemical
environment changes, the 31P chemical shift of the phosphorus atoms
in LPS provides an ideal indicator of the mode of interaction. As shown
Fig. 3. Interaction of HAL-2 with LPS. (A) Secondary structures of 0.2 mg/mL HAL-2 in the absence and presence of LPS from E. coli 055:B5 in 20 mM Tris (pH 7.4) at 298 K. (B) One-
dimensional 31P NMR spectra of 4 mg/mL LPS and the spectra after additions of different concentrations of HAL-2 (pH 7.4, 298 K), showing the changes of chemical shifts and the line
broadening of the 31P resonances of LPS. (C) HAL-2 bound to LPS in vitro. Overlay of the 2D 1H–15N HSQC spectra of 15N-labelled HAL-2 with 0 (red), 0.05, 0.5 or 1 mg/mL (blue) LPS
at pH 7.4. (D) SPR assays of HAL-2 and LPS interaction kinetics. HAL-2 was immobilised on a CM5 sensor chip as ligand, and LPS was diluted in a series of concentrations. Values are re-
corded in RU for indicated concentrations of LPS.
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at−1.30 ppm. As the HAL-2 concentration increased, the LPS 31P spec-
tra changed markedly, indicating a structural perturbation rendered by
the peptide (Fig. 3B). First, the LPS micelle peak (−1.30 ppm) experi-
enced a progressive change in linewidth as a function of increasing con-
centrations of the HAL-2 peptide, as well as slight chemical shift
changes. Changes in the other three peaks also emerged, including a
weak peak at about +1.8 ppm, a broad peak around +0.2 ppm, and a
sharp peak at about +0.8 ppm. The signal at +1.8 ppm shifted upﬁeld
as the HAL-2 concentration increased, and it disappeared in the pres-
ence of 0.8 mM HAL-2. Conversely, intensity changes were observed
for the sharp peak at +0.8 ppm and the broad peak at +0.2 ppm. The
dramatic line broadening of 31P resonances (−1.30 ppm) of LPS after
binding to HAL-2 indicated a restricted mobility of the phosphate
groups, which could be due to either larger micelle formations and/or
conformational exchanges among different states of peptide–LPS
complexes. Furthermore, the upﬁeld shift of the 31P resonance
at +1.8 ppm suggested that the chemical environment and/or confor-
mation of some of the phosphates had changed. Taken together, these
data conﬁrmed that LPS provides interaction sites for the cationic pep-
tide and LPS micelles undergo structural changes when complexed
with HAL-2.
Further NMR experiments were conducted to characterise the inter-
action from the HAL-2 perspective. HSQC spectra were recorded on a
15N-labelled HAL-2 sample (1 mM, in 95% buffer, 5% D2O at pH 7.4,
25 °C) with or without LPS (0.05, 0.5 or 1 mg/mL) (Fig. 3C). At
0.05 mg/mL LPS, no obvious spectral change was observed. HAL-2
signals started to decrease when the LPS concentration reached
0.5 mg/mL, and two peaks ( 8.04 ppm/116 ppm; 8.165 ppm/
120 ppm) almost vanished. When 1 mg/mL LPS was added, the ma-
jority of the peaks disappeared in the HSQC spectrum of HAL-2. As
exempliﬁed by the changes of Trp side chain signal, the addition of
LPS reduced the amount of free HAL-2, implying the binding of
HAL-2 to LPS micelles and the formation of a large complex (Fig. 3C).
We also used SPR spectroscopy to investigate the relationship be-
tween HAL-2 and LPS. As illustrated in Fig. 3D, a typical sensorgram
for the binding of the varying concentrations of LPS to HAL-2 is
shown. A rapid enhancement of the RUs of LPS binding to immobilised
HAL-2 demonstrated the direct interaction between HAL-2 and LPS,
and the binding of LPS as analyte to HAL-2 as ligand exhibited a dose-
dependent pattern at concentrations of 1–16 μg/mL. Kinetic analysis
for the interaction of HAL-2 with LPS yielded a mean value of KD =
1.31 × 10−8 M, indicating an evident afﬁnity between HAL-2 and LPS.Fig. 4. Aggregate formation in the interaction between HAL-2 and LPS (A) or HAL-2 and E. coli (
ferent concentrations of HAL-2, as monitored by ThT ﬂuorescence. The concentrations of the p3.4. Aggregation mode in the interaction of LPS and HAL-2
LPS is the major component of the outer membrane of Gram-
negative bacteria and has been thought to evolve for protection of bacte-
ria against antibacterial molecules. Many AMPs show antimicrobial ac-
tivity because of their LPS-neutralising properties. We monitored the
interaction mode between HAL-2 and LPS (Fig. 4A) or E. coli (Fig. 4B)
with the ThT ﬂuorescence. Aggregation occurred once LPS or E. coliwas
added, and this aggregation activity depended on the peptide concentra-
tions, indicating a nucleation-dependent aggregation process. At the
same time, LPS and E. coli showed aggregation in the interaction with
HAL-2. The aggregation in this reaction mixture might exist as either
an intermolecular electrostatic interaction or an intramolecular one.
3.5. Less amyloid formation and antimicrobial activity of HAL-2 mutants
To further investigate the relationship between amyloid formation
and the antimicrobial activity of HAL-2, we constructed three HAL-2 an-
alogues, HAL-2L6(D), HAL-2K8P and HAL-2H9P. The CD experiments
were carried out to determine the secondary structure of HAL-2
analogues (Fig. 5A). Similar toHAL-2, the analogues had randomconfor-
mations in free solution and showed amarked ability to adopt largely β-
sheet structures in the presence of hydrophobic LPS, containing approx-
imately 53.8% (HAL-2L6(D)), 56.9% (HAL-2K8P), 59.7% (HAL-2H9P) of
β-sheet structure. Furthermore, the formation of amyloid aggregates
was also checked by ThT ﬂuorescence. As illustrated in Fig. 5B, the ana-
logues incubated in LPS underwent amyloid aggregation, which was
peptide concentration dependent. However, reductions of ThT intensity
were observed at all concentrations of the peptide analogues, compared
with HAL-2. The inhibition of E. coli by the HAL-2 analogues was further
investigated by assessing cell viability loss within 180 min at pH 7.4.
Compared with HAL-2, the analogues caused almost no reduction in
the number of CFU (Fig. 5C). These observations indicated that the mu-
tations affected the ability of the amyloid formation of the HAL-2 ana-
logues and thus lowered the antimicrobial activity.
4. Discussion
HAL-2, which is among the shortest linear cationic AMPs found in
nature, was ﬁrst isolated from the venom of the eusocial bee
H. sexcinctus, and it has been reported to display a broad spectrumof an-
timicrobial activity against bacteria, fungi or several types of cancer cells
[25]. Bacterial viability counting showed that HAL-2 exhibited anB) at pH 7.4. LPS (1 mg/mL) or E. coli (4 × 108 cfu/mL) in the absence and presence of dif-
eptide were 40, 60, 70, 100, and 140 μM, and ThT was 47 μM.
Fig. 5. Relationship between amyloid formation and antimicrobial activity. (A) CD spectra of peptides (0.2 mg/mL in 20 mM Tris, pH 7.4) in the absence and presence of 2 mg/mL LPS;
(B) peptide amyloid formation measured by ThT ﬂuorescence emission; (C) the comparison of antimicrobial activity between HAL-2 and its analogues at 180 min.
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used propidium iodide (PI) and ﬂow cytometry to assess themembrane
integrity of E. coli ATCC 25922 after treatment with HAL-2; the results
showed that HAL-2 was able to break E. coli membranes, leading to
the staining of DNA by the PI dye (Fig. 2C). The peptide-exposed bacte-
rial cells exhibited a wide range of pronounced changes in their mor-
phology, as demonstrated by the SEM images, while untreatedbacterial cells displayed a smooth bright surfacewith no apparent cellu-
lar debris (Fig. 2D).
Gram-negative bacteria have a cell wall that is rich in acidic lipids
such as LPS and a central peptidoglycan layer, which forms a permeabil-
ity barrier that must be overcome by broad-spectrum AMPs. Many re-
ports have analysed the structures of AMPs in the presence of LPS or
mimetic membranes of Gram-negative bacteria to understand the
2917J. Wang et al. / Biochimica et Biophysica Acta 1838 (2014) 2910–2918mechanism of LPS or lipid-membrane recognition by AMPs [31–33].
However, the details of the interaction between AMPs and LPS and the
relationship between themechanisms of LPS recognition and structures
of AMPs have not yet been revealed. HAL-2 possesses four basic residues
at pH 7.4, leading to a cationic +4 global charge, so a preferred interac-
tion with the anionic lipid is probable. HAL-2 also contains a histidine
residue in the amino acid sequence. It has been suggested that at pH
values below the pKa of the histidine groups (pKa 6.5), histidine resi-
dues may be protonated, resulting in an increase in the positive net
charge of the corresponding peptide. Hepcidin, a histidine containing
AMP, has been reported to have a pH-dependent antimicrobial activi-
ty [29]. In fact, a stronger effect on E. coli was observed at pH 5.0 (data
not shown), suggesting a differentmode of LPS interaction. This electro-
static interaction between the positively charged residues in HAL-2 and
the negatively charged lipidmay contribute to the recruitment of HAL-2
to the bacterial surface and to the conformational changes for HAL-2
upon lipid binding.
To study the secondary structure of HAL-2 in the absence and pres-
ence of LPS, we performed CD spectroscopy. HAL-2 that was freshly dis-
solved in 20 mM Tris buffer with LPS displayed a peak with negative
ellipticity at approximately 210 nm and a peak with positive ellipticity
at 195 nm, peaks that are characteristic of β-sheet structures (Fig. 3A).
Deconvolution of this spectrum estimated the proportion of secondary
structures to be 15.5% α-helix, 53.3% β-sheet, 6.7% turn and 24.5% ran-
dom coil. In TFE/water mixtures, CD experiments (data not shown)
showed that HAL-2 folds into an α-helical structure. This is consistent
with a previous report that HAL-2 forms an α-helical structure in the
presence of TFE or SDS, and an amphipathic helical model has been pro-
posed where the hydrophilic amino acid residues are situated on one
side of the α-helix and the hydrophobic amino acid residues are on
the opposite side. However, when HAL-2 is in the presence of LPS,
more β-sheet (53.3%) conformation, compared with α-helical confor-
mation, is induced. This ﬁnding was further conﬁrmed by the ThT ex-
periments, where the ﬂuorescent dye ThT bound to ﬁbrils, indicating
the aggregation of the amyloidogenic proteins. The ThT ﬂuorescence in-
tensity increasedwhen LPS or E. coliwas added to the peptides, orwhen
the peptides were added to LPS or E. coli, although LPS or E. coli alone
also exhibited ThT ﬂuorescence (Fig. 4). Taken together, these results
suggest that LPS or E. coli could induce the amyloid aggregation of
HAL-2, which leads to secondary structure changes of HAL-2 (Fig. 3A).
LPS covers N70% of the outer leaﬂet of Gram-negative bacteria [34],
and the antimicrobial peptides have to transverse this outer membrane
and reach the inner phospholipid layer to promote bacterial death. A
previous study suggested an “AMP trap” model, in which LPS induces
the peptide to form a bulky compound that is unable to insert into the
microbial membrane, effectively inactivating the peptide with a mini-
mal inhibitory concentration of approximately 100 μM. The incorpora-
tion of D-amino acids can overcome this “trapping” mechanism by
preventing the formation of oligomers, which allows the peptide to tra-
verse through the LPS outer membrane. The correspondingminimal in-
hibitory concentrationwas lowered to 5 μM[35]. In this study,we found
that once HAL-2 interacted with LPS, peptide aggregation was triggered
and amyloid was formed. As the peptide concentration increased, more
amyloid formed (Fig. 4) and a greater loss of bacterial viability was ob-
served (Fig. 2), indicating a positive correlation between the amyloid
formation and the antimicrobial activity of HAL-2. As shown in Fig. 2A,
the effective antimicrobial concentration of HAL-2 peptide is below
20 μM, which is signiﬁcantly lower than that of “AMP trap” peptide.
For the HAL-2 analogues, less amyloid aggregation formed in the pres-
ence of LPS, and most of the antimicrobial activity was lost, compared
with the wild type HAL-2 peptide. These observations provide strong
evidence that amyloid formation is indeed essential for the antimicrobi-
al activity of HAL-2.
A similar amyloid forming property has been studied in vitro for
other antimicrobial peptides in the presence of lipid membranes
[36–39], and a “leaky slit” model was proposed based on amyloidformation by AMPs on the membrane surface [40]. These studies were
limited to artiﬁcial lipid membranes, so the effect of AMP amyloid
with LPS, which forms the bacterial cell wall barrier, has not been
discussed. Interestingly, some amyloid peptides that are known for
their close relevance to human diseases, including type II diabetes
[41], Creutzfeldt–Jakob disease [42], and Abeta of Alzheimer's disease
[43], have also been found to have antimicrobial activities that normally
function in the innate immune system in response to infections. We
speculate that amyloid aggregation may lead to the toxicity and the an-
timicrobial activity of some peptides, possibly as the result of the bind-
ing of the peptide in an aggregated state, but as yet unknown factors
regulate that speciﬁc binding and aggregation.
The interaction between HAL-2 and LPS is very complicated, and
questions of how the negatively charged LPS surface induces amyloid
formation and how the HAL-2 amyloid causes cell leakage remain to
be elucidated. In our experiments, HAL-2 was conﬁrmed to interact
with LPS by SPR data (Fig. 3D), and a strong interaction between them
was observed (washingwith 140 μMHAL-2was necessary to thorough-
ly regenerate the sensor chip), yielding a value of KD = 1.31 × 10−8 M.
An isothermal titration calorimetry (ITC) experiment was also per-
formed to investigate the binding of HAL-2 to LPS (data not shown),
but an accurate binding constant could not be extracted from the ob-
tained titration curves; multiple factors may contribute to the enthalpy
of binding of the peptides to LPS, as reported in a similar system [44].
Moreover, 1H–15N HSQC and 31P experiments were performed to char-
acterise HAL-2 and LPS interaction from both peptide and lipid perspec-
tive. The line-broadening of HAL-2 HSQC resonances and an LPS 31P
peak at −1.30 ppm suggest the formation of HAL-2/LPS complexes
(Fig. 3B and C). The changes emerging from multiple 31P peaks
(−1.3 ppm, +1.8 ppm, +0.2 ppm, and +0.8 ppm) upon HAL-2 bind-
ing indicate that the phosphate head groups of LPS within the sample
experienced various local chemical environments. Due to the complex-
ity of LPS 31P spectra upon HAL-2 binding, wewere not able to trace the
31P resonance assignments and analyse the interaction details. More-
over, the behaviour of these resonances varied as the HAL-2 concentra-
tion increased, including line broadening, signal disappearance and
frequency shifts, indicating complex structural and dynamic differences
in the lipid molecules. The heterogeneity associated with LPS composi-
tions, which is not demonstrated in the LPS only spectrum,may contrib-
ute to the complex phase and dynamics behaviours of LPS upon HAL-2
binding.
In conclusion, this study sheds light on several clues regarding the
molecularmechanismof the antimicrobial peptide HAL-2. After electro-
statically binding to LPS, HAL-2 adopts a β-strand conformation and
consequently forms amyloid aggregates. Importantly, this amyloid
state makes it possible for the HAL-2 to traverse through the LPS outer
membrane and disrupt the integrity of the inner membrane (Fig. 2C).
However, the incorporation of D-amino acid and proline substitutions
can prevent its antimicrobial activity, and less amyloid aggregation oc-
curs.We propose that the aggregation state may play an important role
in HAL-2 antimicrobial activity. Overall, this study increases our under-
standing of the molecular basis of the antimicrobial activity mediated
by LPS, and it could provide information to design novel antimicrobial
peptides for future therapeutic purposes.
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